Improving the health, safety, and quality of life of our youngest patients

Medical devices designed for kids lag five to ten years behind adult technologies. We are funded by the FDA’s Office of Orphan Products Development to help pediatric device innovators accelerate high-value, high-impact solutions towards commercialization and clinical use.

Our Mission

The UCSF-Stanford PDC aims to improve the health, safety, and quality of life of pediatric patients by accelerating high-value, high impact pediatric device solutions at all stages of the total product lifecycle towards commercialization.

CONGRATULATIONS to the below on being selected as a finalist for the UCSF-Stanford Pediatric Device Consortium’s 2025 Accelerator Pitch Competition!

Our Finalists are:

· AVaTAR (Aortic Valve Trileaflet Autologous Reconstruction): A pediatric surgical device to reconstruct growth-accommodating valves using autologous pericardium, ensuring precision and efficiency; AVaTAR MedTech

· EZSpeech: An AI-powered speech therapy app that guides children with engaging exercises, assesses progress, and provides real-time feedback; EzSpeech AI

· MadSci Smart Shunt: A first-in-class electromechanical CSF shunt that monitors intracranial pressure and optimizes treatment for hydrocephalus patients; Madison Scientific Inc. & University of Wisconsin-Madison

· Nen: Evidence-based health designed for children’s minds to improve their lives; Nen Health

· P-EVPS (Pediatric Ex Vivo Preservation System): Novel pediatric organ preservation system; Stanford University

· RAPIDscan: Pediatric self-driving ultrasound system; Bloom Standard Inc.

· Soluu: A wearable bedwetting mitigation device; Global Continence Inc.

· Sonura Beanie: A beanie hat that provides auditory protection and parental connection for infants with neonatal abstinence syndrome to promote growth and development; Sonura Care Inc. & University of Pennsylvania

· Trach Sense: A lifesaving monitoring device for pediatric tracheostomy patients; Children's National Hospital

· UltraTrac: An ultrasound-guided continuous noninvasive hemodynamic monitor with data analytics; AcQumen Medical

UCSF Stanford PDC Pitch Competition 2025 will be at Stanford University on Monday, March 17, 2025.

Resources

Advising

Learn about our tiers of support for pediatric device innovators.

Funding

Congratulations to the PDC Accelerator Shark Tank 2020 awardees!

Education

Resources and video learning modules for pediatric device innovators.

RWE CONSULTING

Harness the power of real-world evidence in your innovation.

Events

INNOVATORS FORUM: Tuesdays, 4:00-5:00pm Pacific, Virtual via Zoom
If you are interested in attending or presenting at a future Innovators Forum, please email Durgadevi.Pisharam@ucsf.edu

News

Featured
Congratulations to the following to become the finalist for the PDC Pitch 2025 Competetion
Finalist pic 2.jpg
Recap: Michael R. Harrison Innovation Symposium
New pain management therapy cleared for use in adolescents thanks to a groundbreaking collaboration between the UCSF-Stanford PDC, AtriCure, Inc., and the U.S. FDA

A new pain management therapy has been cleared for use in adolescents thanks to a groundbreaking collaboration between the UCSF-Stanford Pediatric Device Consortium (PDC), AtriCure, Inc., and the U.S. Food and Drug Administration (FDA).

On January 4th, AtriCure announced that the FDA cleared its cryo nerve block (cryoNB) devices cryoICE ® and cryoSPHERE™ for post-operative pain management in patients aged 12 and above. The expanded claims were allowed based on real-world evidence (RWE) developed by researchers at the PDC. RWE is an emerging area of regulatory science where evidence derived from real-world data (captured outside of traditional clinical trial settings) is used to evaluate the potential risks and benefits of a device or drug and inform regulatory decision making.

The UCSF-Stanford Pediatric Device Consortium is funded by the U.S. Food & Drug Administration's Office of Orphan Products Development under grant no. P50FD007967.